Drug Profile
TIMP-2 gene therapy
Latest Information Update: 29 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Gene therapies
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Coronary artery restenosis
Most Recent Events
- 29 Apr 2002 No development reported - Preclinical for Coronary artery restenosis in USA (IV)
- 02 Mar 1999 Preclinical development for Cancer in Italy (SC)
- 02 Mar 1999 An animal study has been added to the pharmacodynamic section of Cancer chemotherapy